Related references
Note: Only part of the references are listed.Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
Estefania Garcia-Guerrero et al.
LEUKEMIA (2021)
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
Teru Hideshima et al.
LEUKEMIA (2021)
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
Vipul Sheth et al.
BONE MARROW TRANSPLANTATION (2021)
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Mehmet Kemal Samur et al.
NATURE COMMUNICATIONS (2021)
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
James R. Berenson et al.
CLINICAL CANCER RESEARCH (2020)
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Deepak Perumal et al.
CLINICAL CANCER RESEARCH (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah et al.
LEUKEMIA (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak
Mengyuan Dai et al.
CANCER DISCOVERY (2020)
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
Robert David Sandler et al.
FRONTIERS IN IMMUNOLOGY (2020)
Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
Chiara Caraccio et al.
FRONTIERS IN IMMUNOLOGY (2020)
Cancer immunoediting and immune dysregulation in multiple myeloma
Kyohei Nakamura et al.
BLOOD (2020)
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications
Daisuke Ogiya et al.
BLOOD (2020)
Cancer immunotherapy with γδ T cells: many paths ahead of us
Dieter Kabelitz et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Management of patients with multiple myeloma during the COVID-19 pandemic
Florent Malard et al.
LANCET HAEMATOLOGY (2020)
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Bo Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Determinants of COVID-19 disease severity in patients with cancer
Elizabeth V. Robilotti et al.
NATURE MEDICINE (2020)
Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma
Daniel W. Sherbenou et al.
CLINICAL CANCER RESEARCH (2020)
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
Chen Zhu et al.
FRONTIERS IN IMMUNOLOGY (2020)
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie et al.
EBIOMEDICINE (2020)
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models
Shih-Feng Cho et al.
BLOOD ADVANCES (2020)
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Kodandaram Pillarisetti et al.
BLOOD ADVANCES (2020)
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Abi Vijenthira et al.
BLOOD (2020)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Ajai Chari et al.
BLOOD (2020)
Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma
Lilly Wong et al.
BLOOD (2020)
Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application
Annamaria Gulla et al.
BLOOD (2020)
Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma
Shaji K. Kumar et al.
BLOOD (2020)
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
Tengteng Yu et al.
BLOOD CANCER JOURNAL (2020)
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma
Carlos Fernandez de Larrea et al.
BLOOD CANCER DISCOVERY (2020)
Bone marrow niches in haematological malignancies
Simon Mendez-Ferrer et al.
NATURE REVIEWS CANCER (2020)
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno et al.
CLINICAL CANCER RESEARCH (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Thomas Martin et al.
BLOOD CANCER JOURNAL (2019)
Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
Chuang Sun et al.
Oncotarget (2019)
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Adam S. Sperling et al.
BLOOD (2019)
Phase 1b trial of pembrolizumab monotherapy for relapsed/ refractory multiple myeloma: KEYNOTE-013
Vincent Ribrag et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Zafar Usmani et al.
LANCET HAEMATOLOGY (2019)
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Alfonso Serrano-del Valle et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma
Lijie Xing et al.
BLOOD (2019)
Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study
Rasmus Sorrig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
The extended 4-year follow-up results of the ELOQUENT-2 trial
Maria Gavriatopoulou et al.
Oncotarget (2019)
CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Federica Costa et al.
CELLS (2019)
Cellular Immunotherapy for Multiple Myeloma
Jacalyn Rosenblatt et al.
CANCER JOURNAL (2019)
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
Alfred L. Garfall et al.
BLOOD ADVANCES (2019)
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
Mary E. Matyskiela et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Irene M. Ghobrial et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR
Trudy Straetemans et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W. C. J. van de Donk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma A Nonrandomized Clinical Trial
Ajay K. Nooka et al.
JAMA ONCOLOGY (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
Stina Wichert et al.
PLOS ONE (2017)
The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy
Nicole Rufo et al.
TRENDS IN CANCER (2017)
Advances in immunotherapy in multiple myeloma
Leora Boussi et al.
CURRENT OPINION IN ONCOLOGY (2017)
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik et al.
CLINICAL CANCER RESEARCH (2017)
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
Xiaoyan Feng et al.
CLINICAL CANCER RESEARCH (2017)
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
Teru Hideshima et al.
BLOOD (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Andrzej Jakubowiak et al.
BLOOD (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System
Vivien J. Coulson-Thomas et al.
OCULAR SURFACE (2016)
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide
Deepika S. Das et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Resolving the daratumumab interference with blood compatibility testing
Claudia I. Chapuy et al.
TRANSFUSION (2015)
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Sarah A. Laurent et al.
NATURE COMMUNICATIONS (2015)
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
Balaji Balasa et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Lenalidomide induces degradation of IKZF1 and IKZF3
Jan Kroenke et al.
ONCOIMMUNOLOGY (2014)
The role of B7 family molecules in hematologic malignancy
Paul Greaves et al.
BLOOD (2013)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes
Jessica Dement-Brown et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
Michael. S. van der Veer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression
Mu Hao et al.
LEUKEMIA & LYMPHOMA (2011)
Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
Zhengzi Qian et al.
LEUKEMIA RESEARCH (2011)
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Yulia N. Demchenko et al.
BLOOD (2010)
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Enrique M. Ocio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
Jerome Moreaux et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Radek Spisek et al.
BLOOD (2007)
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma
T. Ise et al.
LEUKEMIA (2007)
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma:: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
An extended family of Fc receptor relatives
RS Davis et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
BCMA is essential for the survival of long-lived bone marrow plasma cells
BP O'Connor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
D Gupta et al.
LEUKEMIA (2001)
IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy
G Hatzivassiliou et al.
IMMUNITY (2001)
Share Paper
